Recombinant Factor FVIII Fc Fusion Protein Linked to Rapid Tolerization in Severe Hemophilia A With Inhibitors
Fitusiran Prophylaxis Linked to Improved Bleeding Rates for Severe Hemophilia A or B Without Inhibitors
Inotuzumab Ozogamicin, Blinatumomab May Be Superior to Chemotherapy in Some Elderly Patients With B-Cell ALL